In Brief There appears to be no stopping legal AI startup Harvey’s skyrocketing growth, with VCs continuously throwing money at it. The company is reportedly in talks to raise another $200 million at an $11 billion valuation led by Sequoia and Singapore’s GIC, sources told Forbes. If the deal closes, Harvey’s valuation would jump by $3 billion in a matter of months. In December the company confirm...
In Brief There appears to be no stopping legal AI startup Harvey’s skyrocketing growth, with VCs continuously throwing money at it. The company is reportedly in talks to raise another $200 million at an $11 billion valuation led by Sequoia and Singapore’s GIC, sources told Forbes. If the deal closes, Harvey’s valuation would jump by $3 billion in a matter of months. In December the company confirmed it had raised $160 million at an $8 billion valuation led by Andreessen Horowitz last fall. (Harvey declined to comment on its potential new raise.) Back in June, it announced a $300 million Series E at a $5 billion valuation led by Kleiner Perkins and Coatue. A few months before that, in February 2025, it gobbled up a Sequoia-led $300 million Series D at a $3 billion valuation. The startup, which offers an LLM AI for law firms, hit an annual recurring revenue rate of $190 million by the end of 2025, founder CEO Winston Weinberg shared on LinkedIn. That was up from a $100 million ARR in August (depending on what the company means by ARR), so that’s nearly double the contracted revenue in less than six months. How has it become one of the breakout winners of AI enterprise applications? Weinberg recently told TechCrunch’s editor-in-chief Connie Loizos an incredible story of how the company originally claimed the hearts of Silicon Valley’s powerhouse VCs.
The U.S. Food and Drug Administration (FDA) has accused Novo Nordisk ( NVO ) ( NONOF ) of violating federal law by including “misleading” claims in a TV commercial for its recently launched oral weight loss therapy, the Wegovy pill. The regulator sent a letter to the Danish drugmaker on Thursday notifying the company to take immediate corrective action, including a potential discontinuation of all...
The U.S. Food and Drug Administration (FDA) has accused Novo Nordisk ( NVO ) ( NONOF ) of violating federal law by including “misleading” claims in a TV commercial for its recently launched oral weight loss therapy, the Wegovy pill. The regulator sent a letter to the Danish drugmaker on Thursday notifying the company to take immediate corrective action, including a potential discontinuation of all promotional campaigns containing the alleged misleading claims. The FDA noted that “live lighter,” “a way forward,” and several other phrases used in the advertisement imply that the Wegovy pill offers superior efficacy and safety over other GLP-1 treatments approved for weight loss. “Specifically, these claims and presentations misleadingly imply that Wegovy in pill form uniquely enables patients to achieve outcomes that were not previously possible with other GLP-1 treatments for weight loss,” the agency said in the letter dated Feb. 5. Novo ( NVO ) has 15 days to submit a written response detailing any plans to cease all communications that are allegedly in violation of the law and, if it believes that its promotional activities comply with the law, to provide reasoning to back up those claims. The company confirmed it received the letter and stated that it has been running the advert since the launch of the Wegovy pill in January. “We take all regulatory feedback seriously and are in the process of responding to the FDA to address their concerns regarding the advertisement’s presentation,” added Liz Skrbkova, head of U.S. media and stakeholder relations for NVO. Novo ( NVO ) aired a star-studded Super Bowl ad on Sunday, its first-ever commercial for football’s biggest event, as the company tries to regain market share lost to weight loss rival Eli Lilly ( LLY ) and companies such as Hims & Hers ( HIMS ), which market compounded GLP-1s. After regulatory pushback, HIMS abandoned its plans to offer cheaper compounded versions of the Wegovy pill on Saturday. However, Novo ...
The stock has been fairly stable over the past year. Pfizer (PFE 0.77%) has been an underwhelming stock to own in recent years. Question marks about its growth and how it will do in the future, as it faces multiple patent cliffs, have resulted in investors steering away from the stock entirely. Despite persistently trading at a low valuation, there hasn't been a compelling reason for investors to ...
The stock has been fairly stable over the past year. Pfizer (PFE 0.77%) has been an underwhelming stock to own in recent years. Question marks about its growth and how it will do in the future, as it faces multiple patent cliffs, have resulted in investors steering away from the stock entirely. Despite persistently trading at a low valuation, there hasn't been a compelling reason for investors to load up on the stock -- it's down 38% over the past three years. There could, however, be one enticing reason to buy the stock, and that's for its dividend. At 6.3%, the payout is significantly higher than what you'd get with the average stock on the S&P 500 , which pays just 1.1%. Could Pfizer be an underrated option for income investors? Is Pfizer's dividend safe? The big question for dividend investors when it comes to a high-yielding dividend is whether it's sustainable. While everyone would love to collect a high payout, no one wants it to get cut. And that's often the biggest risk with high-yielding stocks, whether a reduction to the payout is around the corner. Pfizer recently posted its year-end results, and its diluted earnings per share came in at $1.36. That's well below the rate of its annual dividend of $1.72 per share, raising question marks about just how safe the dividend is. But the company has reported billions in asset impairment charges that have weighed on its results. For 2026, Pfizer forecasts that its adjusted per-share earnings will be within a range of $2.80 to $3.00. While that's on an adjusted basis, it does suggest that there may be a bit more safety with the dividend than there appears to be at first glance. Expand NYSE : PFE Pfizer Today's Change ( -0.77 %) $ -0.21 Current Price $ 27.01 Key Data Points Market Cap $155B Day's Range $ 26.79 - $ 27.36 52wk Range $ 20.91 - $ 27.69 Volume 884K Avg Vol 58M Gross Margin 76.10 % Dividend Yield 6.32 % Why Pfizer could make for a solid dividend stock to own Pfizer's revenue declined by 2% this past year...
The stock hasn't been trading around these levels since June of last year. Robinhood Markets (HOOD +5.78%) reports its latest earnings numbers tomorrow, and the stock could use a boost. Entering trading on Monday, shares of Robinhood were down 22% since the start of the year. Despite posting some strong growth in recent quarters, the stock has been coming under some significant pressure of late. W...
The stock hasn't been trading around these levels since June of last year. Robinhood Markets (HOOD +5.78%) reports its latest earnings numbers tomorrow, and the stock could use a boost. Entering trading on Monday, shares of Robinhood were down 22% since the start of the year. Despite posting some strong growth in recent quarters, the stock has been coming under some significant pressure of late. What is behind the stock's recent downturn, and could there be more trouble ahead for Robinhood, or could this be an ideal time to load up on the growth stock? Could Bitcoin be to blame for Robinhood's struggles? Robinhood's trading platform makes it easy for people to buy and sell stocks, and also crypto, which has been a huge growth catalyst for its business. When the company last reported earnings in November, it experienced 129% growth in transaction-based revenues, with cryptocurrencies being a huge part of that. Cryptocurrency-related revenue rose by a staggering 300%. Perhaps unsurprisingly, then, as Bitcoin has fallen sharply in value this year, Robinhood has struggled as well. There has historically been a strong correlation between the value of Bitcoin and Robinhood's stock performance, as is evident in the chart below. If there's been a softening in the cryptocurrency markets, that may not bode well for trading levels on Robinhood's platform, and investors may be adjusting their expectations accordingly. Has the stock become a cheap buy? Robinhood's sudden decline in value has brought it down to a more reasonable valuation. Currently, it's trading at a price-to-earnings multiple of around 37. While that isn't terribly low, it's far lower than the 70 times earnings it has traded at in the past. For a company that's growing at such a fast and feverish pace, and with some exciting opportunities in the prediction markets, some premium is arguably justifiable for Robinhood's stock. An earnings multiple of less than 40 could be attractive for a business that has been do...
Trump's Venezuela Tanker Crackdown Goes Global With Indian Ocean Interdiction U.S. forces boarded the crude tanker Aquila II in the Indian Ocean after tracking it from the Caribbean, the Department of War disclosed on X early Monday. Officials accuse the vessel of violating Washington's quarantine on sanctioned tankers moving to or from Venezuela. "When the @DeptofWar says quarantine, we mean it. ...
Trump's Venezuela Tanker Crackdown Goes Global With Indian Ocean Interdiction U.S. forces boarded the crude tanker Aquila II in the Indian Ocean after tracking it from the Caribbean, the Department of War disclosed on X early Monday. Officials accuse the vessel of violating Washington's quarantine on sanctioned tankers moving to or from Venezuela. "When the @DeptofWar says quarantine, we mean it. Nothing will stop DoW from defending our Homeland — even in oceans halfway around the world," DoW wrote on X. DoW said U.S. forces boarded the tanker Aquila II in the United States Indo-Pacific Command (USINDOPACOM) area. It claims Aquila II was evading President Trump's quarantine of sanctioned vessels in the Caribbean area. pic.twitter.com/sh8J61RC8Y — Department of War 🇺🇸 (@DeptofWar) February 9, 2026 "The Department of War tracked and hunted this vessel from the Caribbean to the Indian Ocean. No other nation on planet Earth has the capability to enforce its will through any domain. By land, air, or sea, our Armed Forces will find you and deliver justice. You will run out of fuel long before you will outrun us," DoW emphasized on X. When the @DeptofWar says quarantine, we mean it. Nothing will stop DoW from defending our Homeland — even in oceans halfway around the world. Overnight, U.S. military forces conducted a right-of-visit, maritime interdiction and boarding on the Aquila II without incident in the… pic.twitter.com/kYVAQC5io9 — Department of War 🇺🇸 (@DeptofWar) February 9, 2026 Reuters reports the Aquila II departed Venezuela's waters in early January carrying roughly 700,000 barrels of heavy crude bound for China. Shipping data did not clearly identify the vessel's flag or registration. The U.S. has seized or "apprehended" seven Venezuela-linked, sanctioned tankers under Trump's quarantine enforcement effort , otherwise known as Gunboat Diplomacy, with most interdictions occurring in the Caribbean Sea. One of the more daring interdictions occurred in the Atlantic...
Key Points Alphabet is seeing some solid results from its Willow chip. Nvidia ties traditional and quantum computing together. IonQ is the quantum computing accuracy leader. 10 stocks we like better than IonQ › Quantum computing has taken a step back in popularity over the past few months. After peaking in interest in October, many quantum computing stocks have sold off a healthy amount. However, ...
Key Points Alphabet is seeing some solid results from its Willow chip. Nvidia ties traditional and quantum computing together. IonQ is the quantum computing accuracy leader. 10 stocks we like better than IonQ › Quantum computing has taken a step back in popularity over the past few months. After peaking in interest in October, many quantum computing stocks have sold off a healthy amount. However, since quantum computing hype is at a relative low, now is the time investors should consider scooping up shares. But this doesn't mean going out and buying the stocks of every quantum computing pure play on the market. There will be a lot of busts from that sector, and investors must keep a balanced approach. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » By also choosing stocks of legacy tech companies competing in quantum computing, investors can generate great returns while still ensuring they aren't taking on too much risk. I think approaching quantum computing in this way is a smart move. If you've got $3,000, investing $1,000 in each of these stocks could be wise. Alphabet Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) is a major player in the quantum computing realm. It has resources the pure plays can only dream of, and it is delivering strong quantum computing results. Its Willow chip is one of the more accurate options available and is already delivering real-world application success. That's a major hurdle in the quantum computing realm, and if Alphabet can prove its relevance before anyone else does, it will be a massive winner. One nice benefit of investing in Alphabet is that you get the upside of quantum computing, alongside a massive winner in the generative artificial intelligence (AI) arena. Alphabet's generative AI model Gemini has emerged as one of the best available and could be the ultimate market winner years down the road. Even without ...
Key Points Walmart's price-to-earnings multiple of 45 is high in relation to the S&P 500. The business has been resilient over the years, but its growth rate is typically in the single digits. 10 stocks we like better than Walmart › Walmart (NASDAQ: WMT) is an iconic big-box retailer that customers rely on every day for both necessities and discretionary purchases. And the company's resiliency ove...
Key Points Walmart's price-to-earnings multiple of 45 is high in relation to the S&P 500. The business has been resilient over the years, but its growth rate is typically in the single digits. 10 stocks we like better than Walmart › Walmart (NASDAQ: WMT) is an iconic big-box retailer that customers rely on every day for both necessities and discretionary purchases. And the company's resiliency over the years has made it a go-to investment for all types of investors. Over the past 12 months, it has risen by 28% in value, which has pushed its valuation to a market cap of just over $1 trillion. It's a huge milestone for the business, symbolizing just how special it really is, with it being one of the only non-tech stocks in the trillion-dollar club. But does that also mean the stock has become deeply overvalued? Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Just how expensive is Walmart's stock? A $1 trillion market cap may sound high, but to truly gauge how expensive or cheap a stock is, it's important to turn to the price-to-earnings (P/E) multiple, which puts the valuation into context of earnings. Currently, Walmart's stock trades at a P/E of 45. Here's how that compares to other retail stocks. There's a wide discrepancy between what investors are willing to pay for poor-performing retail businesses (such as Target) versus ones that are doing exceptionally well, like Walmart and Costco Wholesale. But the big question is whether valuations have gotten out of hand; Walmart's five-year average P/E ratio is 35. And the S&P 500 averages a multiple of just 25. Investors have been loading up on safe-haven stocks such as Walmart in droves, and that has driven its valuation incredibly high. The problem is that its growth rate may not be high enough to suggest that the premium is warranted. Why the valua...
Key Points Pfizer recently reported earnings, which weren't terribly impressive. Concerns about its future growth have weighed on its valuation in recent years. Impairment charges have impacted its bottom line, making it look worse than it otherwise would have been. 10 stocks we like better than Pfizer › Pfizer (NYSE: PFE) has been an underwhelming stock to own in recent years. Question marks abou...
Key Points Pfizer recently reported earnings, which weren't terribly impressive. Concerns about its future growth have weighed on its valuation in recent years. Impairment charges have impacted its bottom line, making it look worse than it otherwise would have been. 10 stocks we like better than Pfizer › Pfizer (NYSE: PFE) has been an underwhelming stock to own in recent years. Question marks about its growth and how it will do in the future, as it faces multiple patent cliffs, have resulted in investors steering away from the stock entirely. Despite persistently trading at a low valuation, there hasn't been a compelling reason for investors to load up on the stock -- it's down 38% over the past three years. There could, however, be one enticing reason to buy the stock, and that's for its dividend. At 6.3%, the payout is significantly higher than what you'd get with the average stock on the S&P 500 , which pays just 1.1%. Could Pfizer be an underrated option for income investors? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » Is Pfizer's dividend safe? The big question for dividend investors when it comes to a high-yielding dividend is whether it's sustainable. While everyone would love to collect a high payout, no one wants it to get cut. And that's often the biggest risk with high-yielding stocks, whether a reduction to the payout is around the corner. Pfizer recently posted its year-end results, and its diluted earnings per share came in at $1.36. That's well below the rate of its annual dividend of $1.72 per share, raising question marks about just how safe the dividend is. But the company has reported billions in asset impairment charges that have weighed on its results. For 2026, Pfizer forecasts that its adjusted per-share earnings will be within a range of $2.80 to $3.00. While that's on an adjusted basis, it does suggest that there may ...
Key Points The falling price of Bitcoin in recent months may be responsible for Robinhood's stock performance. Cryptocurrency trading is a big part of the company's operations. Robinhood's valuation remains high, but it's not as egregious as it has been in the past. 10 stocks we like better than Robinhood Markets › Robinhood Markets (NASDAQ: HOOD) reports its latest earnings numbers tomorrow, and ...
Key Points The falling price of Bitcoin in recent months may be responsible for Robinhood's stock performance. Cryptocurrency trading is a big part of the company's operations. Robinhood's valuation remains high, but it's not as egregious as it has been in the past. 10 stocks we like better than Robinhood Markets › Robinhood Markets (NASDAQ: HOOD) reports its latest earnings numbers tomorrow, and the stock could use a boost. Entering trading on Monday, shares of Robinhood were down 22% since the start of the year. Despite posting some strong growth in recent quarters, the stock has been coming under some significant pressure of late. What is behind the stock's recent downturn, and could there be more trouble ahead for Robinhood, or could this be an ideal time to load up on the growth stock? Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Could Bitcoin be to blame for Robinhood's struggles? Robinhood's trading platform makes it easy for people to buy and sell stocks, and also crypto, which has been a huge growth catalyst for its business. When the company last reported earnings in November, it experienced 129% growth in transaction-based revenues, with cryptocurrencies being a huge part of that. Cryptocurrency-related revenue rose by a staggering 300%. Perhaps unsurprisingly, then, as Bitcoin has fallen sharply in value this year, Robinhood has struggled as well. There has historically been a strong correlation between the value of Bitcoin and Robinhood's stock performance, as is evident in the chart below. If there's been a softening in the cryptocurrency markets, that may not bode well for trading levels on Robinhood's platform, and investors may be adjusting their expectations accordingly. Has the stock become a cheap buy? Robinhood's sudden decline in value has brought it down to a more reasona...
Cunaplus_M.Faba/iStock via Getty Images Dear Investor: During the Fourth Quarter, Third Point returned 1.9% net in the flagship Offshore Fund. Q4 1 ANNUALIZED NETRETURN 2 TP OFFSHORE FUND, LTD. 1.9% 13.1% CS HF EVENT-DRIVEN INDEX 1.1% 6.9% S&P 500 INDEX ( TR ) 2.7% 9.8% MSCI WORLD INDEX ( TR ) 3.2% 8.3% Click to enlarge 1 Through December 31, 2025. 2 Annualized Return from inception (December 1996...
Cunaplus_M.Faba/iStock via Getty Images Dear Investor: During the Fourth Quarter, Third Point returned 1.9% net in the flagship Offshore Fund. Q4 1 ANNUALIZED NETRETURN 2 TP OFFSHORE FUND, LTD. 1.9% 13.1% CS HF EVENT-DRIVEN INDEX 1.1% 6.9% S&P 500 INDEX ( TR ) 2.7% 9.8% MSCI WORLD INDEX ( TR ) 3.2% 8.3% Click to enlarge 1 Through December 31, 2025. 2 Annualized Return from inception (December 1996 for TP Offshore and quoted indices). PLEASE SEE THE NEW SERIES RETURNS AT THE END OF THIS DOCUMENT. The top five winners for the quarter were SK Hynix Inc. ( HXSC.F ), DSV A/S ( DSDVF ), Siemens Energy AG ( SMEGF ), Carpenter Technology Corp. ( CRS ), and Pacific Gas and Electric Co. The top five losers for the quarter, excluding hedges, were CoStar Group Inc. ( CSGP ), Microsoft Corp. ( MSFT ), Meta Platforms Inc. ( META ), Vistra Corp. ( VST ), and Primo Brands Corp ( PRMB ). The trends that drove markets higher during Q4 have extended into the early months of 2026: an ongoing rotation from software into semiconductors, memory, and semicap equipment; continued strength in European defense equities; a broadening of market leadership from big tech to the industrials, healthcare, and consumer sectors; and an astounding appreciation in gold and rare earths. Notwithstanding the extreme volatility and selloff from the intraday peak of nearly $5,600/oz, the price of gold has increased ~15% year-to-date. Meanwhile, Bitcoin is down 20% from its year-end price and down almost 45% from its peak of over $125,000 just last October. AI dominates market headlines and is increasingly forcing a re-think of established beliefs. One of them is the long-perceived attractiveness of capital-light business models like software, information services, and digital platforms that for decades required little to no physical investment to grow and achieve dominance. Many such companies are now facing increased investor skepticism about the sustainability of their moats and scrutiny of their high-marg...
Nicolae Popescu/iStock via Getty Images Alphabet Inc. ( GOOG ) ( GOOGL ) is gaining momentum in Google Cloud, realizing accelerated growth in Q4 ’25 to close the year with an annual run rate of $58.7b. With the segment’s operating margin quickly improving, surpassing 30% in Q4 ’25, I believe the firm is taking the right steps to accelerate growth, doubling the expected capital outlay for eFY26 to ...
Nicolae Popescu/iStock via Getty Images Alphabet Inc. ( GOOG ) ( GOOGL ) is gaining momentum in Google Cloud, realizing accelerated growth in Q4 ’25 to close the year with an annual run rate of $58.7b. With the segment’s operating margin quickly improving, surpassing 30% in Q4 ’25, I believe the firm is taking the right steps to accelerate growth, doubling the expected capital outlay for eFY26 to drive backlog conversion. With Alphabet’s strong growth for Google Cloud along with broad adoption of Gemini AI models, I am upgrading GOOG shares to a Strong Buy with a price target of $402/share at 20.51x eFY27 EV/EBITDA. Alphabet Operational Update Corporate Filings The biggest takeaway from the Q4 ’25 earnings release was the substantial increase in the capital budget to drive growth in cloud compute capacity. Accordingly, management guided a 91-102% increase in capital spend for eFY26 when compared to the 2025 budget of $91.5b. I’ll admit, the figures outlined in the Q4 ’25 earnings call far exceeded my previous forecast , which I had thought was already an aggressive increase. Nonetheless, it should be clear that these investments are being well deployed given the substantial accretive growth realized in the Google Cloud operating segment in Q4 ’25 where the operating margin increased by 637bps sequentially to 30%. What’s just as impressive was the 55% sequential increase in the backlog, adding $85b to close the quarter with $240b in backlog. Corporate Filings Alphabet has seen exceptional success in its Gemini AI platform, accumulating 8mm paid seats for Gemini Enterprise and 750mm monthly active users. One of the factors that should provide comfort to the market is Alphabet’s operational improvements to its AI models, lowering the unit cost by 78% throughout 2025 through optimization, efficiency improvements, and utilization. With news regarding OpenAI’s ( OPENAI ) steep operating losses, which are expected to be -$14b for 2026, I believe Alphabet’s model optimizati...
This article first appeared on GuruFocus. Alphabet, the parent of Google (NASDAQ:GOOGL) stock is in focus on Monday after it moved into the U.S. debt market with a seven-part bond offering as it steps up spending tied to artificial intelligence. Shares of Google rose in premarket trading, but traded flat on the opening bell after the company outlined plans to use the proceeds to support a sharp in...
This article first appeared on GuruFocus. Alphabet, the parent of Google (NASDAQ:GOOGL) stock is in focus on Monday after it moved into the U.S. debt market with a seven-part bond offering as it steps up spending tied to artificial intelligence. Shares of Google rose in premarket trading, but traded flat on the opening bell after the company outlined plans to use the proceeds to support a sharp increase in capital expenditures this year. Alphabet said it expects capital spending to reach about $185 billion in 2026, nearly double the prior year's level. The investment centers on artificial intelligence infrastructure as demand for computing power continues to rise. The bond sale includes multiple maturities, with the longest notes extending into the mid-2060s. Alphabet is offering a premium over comparable U.S. Treasury yields to attract investors. The company said roughly 40% of planned spending will go toward building data centers and network capacity, while the remainder will fund servers and specialized AI chips. Other large technology companies are also leaning on debt markets. Oracle (ORCL) recently completed a large bond offering, while Amazon (AMZN), Microsoft (MSFT), and Meta (META) continue to invest heavily in AI infrastructure. Alphabet said growth in its cloud business, supported by AI services, helped underpin the expanded investment plans.
This article first appeared on GuruFocus. Micron Technology (NASDAQ:MU) shares fell about 2% on Monday following news that Samsung Electronics will begin mass production of next-generation high-bandwidth memory (HBM4) chips earlier than expected. Samsung plans to start large-scale HBM4 production this month, supplying Nvidia (NASDAQ:NVDA) for its next-generation AI accelerator, Vera Rubin. The chi...
This article first appeared on GuruFocus. Micron Technology (NASDAQ:MU) shares fell about 2% on Monday following news that Samsung Electronics will begin mass production of next-generation high-bandwidth memory (HBM4) chips earlier than expected. Samsung plans to start large-scale HBM4 production this month, supplying Nvidia (NASDAQ:NVDA) for its next-generation AI accelerator, Vera Rubin. The chips reportedly exceed previous-generation HBM3E speeds by about 22%, reaching data processing rates of up to 11.7 Gbps. The accelerated timeline may give Samsung an edge over competitors Micron and SK Hynix in supplying AI processors. HBM chips carry higher margins than standard memory, and investors worry Micron could lose market share in this segment. Micron's CEO Sanjay Mehrotra said the company aims to ramp up its own HBM4 production in the second quarter of 2026. Despite the competitive pressure, Nvidia shares climbed about 3%, reflecting strong demand for AI chips. Analysts note that the growing AI infrastructure market is reshaping memory demand, with HBM becoming a critical factor in AI processor performance.
Earnings Call Insights: Dynatrace (DT) Q3 2026 Management View CEO Rick McConnell opened the call by highlighting "very strong third quarter fiscal 2026 results, exceeding our guidance across every metric." He emphasized the company's stabilization of ARR growth at 16%, consistent double-digit net new ARR growth for three quarters, annualized log consumption surpassing $100 million, and the doubli...
Earnings Call Insights: Dynatrace (DT) Q3 2026 Management View CEO Rick McConnell opened the call by highlighting "very strong third quarter fiscal 2026 results, exceeding our guidance across every metric." He emphasized the company's stabilization of ARR growth at 16%, consistent double-digit net new ARR growth for three quarters, annualized log consumption surpassing $100 million, and the doubling of the share repurchase program. McConnell stated, "We are on track to achieve $2 billion in ARR by the end of fiscal '26." McConnell described the launch of Dynatrace Intelligence, calling it "the industry's first agentic operations system built for modern software ecosystems," and explained it as a key driver for future growth. He noted, "Dynatrace Intelligence is embedded in the platform and is not sold as a separate SKU. It is available to every customer today." The CEO also pointed to deeper technical engagements with major hyperscalers and the acquisition of DevCycle to enhance feature management for developers. CFO James Benson reported, "Q3 marked another quarter of strong execution as we once again surpassed the high end of guidance across all our key metrics, showcasing the growing demand for our leading AI-powered observability platform and the durability of our balanced business model." Outlook Dynatrace raised full year guidance across all major metrics. The ARR growth guidance increased by 125 basis points to a range of 15.5% to 16%. Management expects to "surpass our next milestone of delivering over $2 billion in ARR." Total and subscription revenue growth guidance increased by 75 basis points at the midpoint to 16% growth. Non-GAAP EPS guidance was raised to a range of $1.67 to $1.69 per diluted share, representing an increase of $0.05 at the midpoint. Benson stated, "We are raising full year non-GAAP operating income guidance by $9 million and free cash flow by $13 million." Financial Results The company ended the quarter with $1.97 billion in ARR, up 1...
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use ess...
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
I knew him but not well, and worry now that he thrived in our political culture. It was not just failed vetting: there was a failure of moral seriousness • Streeting wrote off his re-election chances in WhatsApp exchanges with Mandelson Politics has a problem with sexism and misogyny. We need to be clear what it is and why. With every scandal there is a call to clean up the system, to reform vetti...
I knew him but not well, and worry now that he thrived in our political culture. It was not just failed vetting: there was a failure of moral seriousness • Streeting wrote off his re-election chances in WhatsApp exchanges with Mandelson Politics has a problem with sexism and misogyny. We need to be clear what it is and why. With every scandal there is a call to clean up the system, to reform vetting procedures and the laws governing the release of sensitive information. Those are serious issues, but we will not fix the problem by starting there because the problem is not procedural. It is about culture and behaviour. In the scandal of Peter Mandelson’s appointment to be the British ambassador to the United States, of course we need to establish the timeline of who said what, to whom and when. Gordon Brown is right to insist on a more rigorous process and a renewed commitment to the redistribution of power. But if we focus solely on what happened we will miss the important question of why it happened. This is more than a story about the flaws of individuals and the flaws of a system. This is about culture and moral character. About how, for too long, proximity to power insulated powerful, wealthy and well-connected men from the consequences of their appalling behaviour towards women and girls. The really worrying aspect is not what took place in secret. It is what happened in plain sight. A candidate’s known association with a convicted sexual predator did not weigh heavily enough on decision-makers. And we need to think too about the silence of those who stood by, who knew enough to feel uneasy and yet did not speak loudly enough to influence the decision. This is a group I include myself in. Contrary to what has been widely reported, I was not a close friend of Peter Mandelson, but I am not going to wash my hands of my actual association with him either. After a weekend of smear and innuendo that I have something to hide, I have decided to publish my messages with ...
In Brief Enterprise resource planning software company Workday announced Monday that chief executive Carl Eschenbach was stepping down and leaving the company’s board, effective immediately. Workday co-founder and former CEO Aneel Bhusri will return as CEO. Eschenbach joined Workday in December 2022 as co-CEO alongside Bhusri, and had been operating as the company’s sole CEO since February 2024. B...
In Brief Enterprise resource planning software company Workday announced Monday that chief executive Carl Eschenbach was stepping down and leaving the company’s board, effective immediately. Workday co-founder and former CEO Aneel Bhusri will return as CEO. Eschenbach joined Workday in December 2022 as co-CEO alongside Bhusri, and had been operating as the company’s sole CEO since February 2024. Bhusri, who had led the company since 2009 — sometimes as co-CEO, sometimes as sole CEO — has been serving as the company’s executive chairman since 2024. Workday confirmed to TechCrunch that Bhusri is returning to the role permanently, as opposed to taking the helm during a search for a replacement. Workday made this leadership change as it says its next chapter will be focused on, unsurprisingly, AI. “We’re now entering one of the most pivotal moments in our history,” Bhusri said in the company’s press release Monday. “AI is a bigger transformation than SaaS — and it will define the next generation of market leaders. I’m energized to return as CEO, working alongside our presidents Gerrit Kazmaier and Rob Enslin, and I’m excited about the opportunity in front of us.” Last February, Workday laid off 8.5% of its headcount, or 1,750 people, with Eschenbach stating at the time that the company needed a new approach to labor in the age of AI.